Actively Recruiting

Age: 18Years +
All Genders
NCT04635111

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Led by Daiichi Sankyo · Updated on 2025-10-06

30

Participants Needed

8

Research Sites

803 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

CONDITIONS

Official Title

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult participants with symptomatic tenosynovial giant cell tumor (TGCT) causing severe morbidity or functional limitations and not amenable to surgery
  • Age 18 years or older
  • At least one liver test abnormality due to TURALIO14 exposure: AST or ALT >3 times upper limit of normal (ULN) with total bilirubin >2 times ULN, or isolated total bilirubin >2 times ULN (excluding Gilbert's syndrome), or isolated AST or ALT >10 times ULN, or alkaline phosphatase >2 times ULN with gamma-glutamyl transferase >2 times ULN
  • Consent to study procedures, long-term safety follow-up, and use of data from the TURALIO14 Risk Evaluation and Mitigation Strategy (REMS) program
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

Kamalesh K Sankhala MD INC

Santa Monica, California, United States, 90403

Actively Recruiting

2

Sarcoma Oncology Research Center LLC

Santa Monica, California, United States, 90403

Not Yet Recruiting

3

UCLA Hematology and Oncology

Santa Monica, California, United States, 90404

Actively Recruiting

4

The Oncology Institute of Hope and Innovation

Whittier, California, United States, 90602

Withdrawn

5

Dana-Farber Cancer Institute

Boston, Massachusetts, United States, 02215

Actively Recruiting

6

Montefiore Medical Center

New York, New York, United States, 10467

Withdrawn

7

OSU - James Comprehensive Cancer Center

Columbus, Ohio, United States, 43210

Actively Recruiting

8

Kelsey Seybold Clinic - Pearland

Houston, Texas, United States, 77014

Not Yet Recruiting

Loading map...

Research Team

D

Daiichi Sankyo Contact for Clinical Trial Information

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here